Past viewpoints on Trichomonas vaginalis infection have characterized the associated clinical disease as a "nuisance" condition, with affected demographics largely being older African American females residing in urban centers. The advent of commercial molecular assays specific for T. vaginalishas offered a new outlook on trichomoniasis. Within high-prevalence sexually transmitted infection populations, parasite distribution is not localized to specific population centers, and T. vaginalis prevalence is elevated among both younger and older age groups. Adaptation of these molecular assays can additionally facilitate male screening and subsequent epidemiologic characterization. These findings, combined with associations between T. vaginalis infection and human immunodeficiency virus (HIV) acquisition/transmission and persistent human papillomavirus infection, support consideration of the expansion of T. vaginalis screening efforts in the realms of clinical practice and public health.
Introduction
The French microscopist, clinician, and researcher A. F. Donné discovered the protozoan T. vaginalis 180 years ago. Trichomoniasis, the clinical entity ascribed to the pathogen, has become the most prevalent non-viral sexually transmitted infection (STI) in the United States (Fig. 1) . A surveillance study conducted by the U.S. Centers for Disease Control and Prevention (CDC) in 2008 estimated trichomoniasis prevalence in this country at 4 million cases, with approximately 1 million new cases of T. vaginalis infection being diagnosed annually. 1 As will be posited and further described throughout this review, several factors impact the true characterization of trichomoniasis. As an introductory example, T. vaginalis prevalence rates are rather disparate on a worldwide basis. In contrast to reports of >20% prevalence in some U.S., African, and indigenous Australian population centers, 2,3,4,5 a number of European, Asian-Pacific, and non-indigenous Australian studies have documented rates lower than 5%. 6, 7, 8, 9, 10 The advent of molecular-based laboratory detection of T. vaginalis has broadened our knowledge of trichomoniasis, allowing new perspectives on disease epidemiology and opportunities for prevention.
In addition, advancements related to diagnostic algorithms have garnered much attention in the clinical research setting. A PubMed primary literature search (U.S. National Library of Medicine and the National Institutes of Health) conducted in February 2016 using the search parameter "Trichomonas vaginalis" filtered by the possibility of "antigen," "molecular testing," "nucleic acid hybridization," "PCR," "nucleic acid amplification testing," "LAMP" (loop-mediated isothermal amplification), or "transcription-mediated amplification" selected 629 primary citations from the years 1964 to 2016, with over 25% published since the beginning of 2012. This brief commentary, with focus largely on literature published within the past 3 years, discusses updates on T. vaginalisepidemiology and laboratory testing.
Epidemiology Females
Trichomoniasis can be characterized by a diffuse, malodorous, yellow-green vaginal discharge with vulvar irritation. 11 While pruritis and dysuria may be present, a majority of T. vaginalis infections are actually thought to be asymptomatic. This has long been a source of consternation for clinicians and researchers in the context of proper laboratory diagnostic strategies and clinical management. Data published nearly 25 years ago stated that approximately one-third of patients with asymptomatic T. vaginalis infection become symptomatic within 6 months, 12 perhaps necessitating additional encounters with health care. Mathematic modeling suggests that the average duration of T. vaginalis infection in women approaches 3 to 5 years. 13 Such data imply indolent T. vaginalis infection in a significant percentage of women, yet the organism has been associated with pregnancy complications, including preterm delivery, low-birthweight delivery, and delivery of offspring later diagnosed with intellectual disability or attention deficithyperactivity disorder. reviewed in reference 14 From a retrospective audit of 108,346 Medicaid recipients [15] it was concluded that females diagnosed with trichomoniasis within the first 7 months of pregnancy were more likely to deliver at ≤33 weeks of gestation (hazard ratio, interval, 1.6 to 3.2]; P < 0.0001). In an investigation of commercial sex workers in Kenya using RNA amplification techniques specific to both STI agents and high-risk HPV, Ting et al. 17 described higher rates of HPV positivity in women also positive for T. vaginalis.
The public health significance of T. vaginalis detection also extends to HIV. From a study of adolescents with behavioral risk factors for HIV infection, Mullins et al. 18 reported a higher T. vaginalis incidence rate in females who were HIV positive (1.3/100 person months) than in those who were not (0.6/100 person months; P = 0.002). Several studies have characterized a role for T. vaginalis in HIV acquisition by females. One prospective study of 4,948 sexually active African females 19 reported that T. vaginalisinfected women were more likely to test positive for HIV at a subsequent health care encounter (adjusted hazard ratio, 2.05 [95% confidence interval, 1.05 to 4.02]). Hughes et al. 20 prospectively studied 3,297 African HIV-serodiscordant couples and found that T. vaginalis infection of the female partner was an independent risk factor for increased probability of HIV acquisition per coital act (odds ratio, 2.57 [95% confidence interval 1.42 to 4.65]).
In similar fashion, studies have elucidated a role for T. vaginalis in HIV transmission. Co-incubation of T. vaginalis with acutely infected peripheral blood mononuclear cells in vitro has been shown to increase the HIV replication rate. 21 A Louisiana cohort with documented infection by both HIV and T. vaginalis were prospectively observed following a course of metronidazole therapy. 22 Successful anti- Compared to commonly assessed STI agents, such as Chlamydia trachomatis and Neisseria gonorrhoeae, the prevalence of T. vaginalis among older females is especially significant. Napierala et al. 24 summarized clinical laboratory testing of a subacute care population within a high-prevalence STI community using commercially available molecular assays for C. trachomatis, N. gonorrhoeae, and T. vaginalis. The T. vaginalis detection rate (9.3%) within a subset of 7,277 females exceeded those of C. trachomatis (5.7%) and N. gonorrhoeae (1.4%; both P < 0.0002). When detection rates were delineated by age decade, 25 the predictable finding of increased T. vaginalis detection versus C. trachomatis detection in patients aged 31 to 60 years was observed (Fig. 2) . A T. vaginalis detection rate of greater than 11% was realized for females over the age of 60; however, the small subset did not allow statistical comparison versus C. trachomatis detection. Novel findings included elevated T. vaginalis detection rates in females under the age of 21 ( Fig. 2) and significantly increased T. Past epidemiologic data, often derived from studies utilizing less sensitive diagnostic assays, have suggested that trichomoniasis is largely an urban disease. When considering the dataset in Fig. 2 , it is important to note that <2% of those data were gathered from females in acute care. 25 By way of STI phenotype calculation (defined as permutations of T. vaginalis, C. trachomatis, and N. gonorrhoeae detection from any health care encounter that resulted in detection of at least one STI)
and comparison of such data 25 with those from acute care 30 and from a combined subacute and acute care cohort, 31 one can ascertain parasite distribution across an entire metropolitan setting. The STI phenotype from subacute care demonstrated the greatest proclivity for sole detection of T. vaginalis (54.2% of health care encounters) ( Table 1 ). In contrast, sole detection of T. vaginalis from acute care was 40.7%. Moreover, phenotypes that involved any detection of T. vaginalis were 63.5%
and 55.8% in the subacute care and acute care populations, respectively. The above-mentioned data flank T. vaginalisphenotypes derived from an overall community setting. 31 These separate large-scale data collections implicate T. vaginalis distribution as being widespread throughout a metropolitan setting and signal the necessity for accurate laboratory diagnostics and clinician utilization of those modalities. Within a high-prevalence STI community, 622 males were screened for C. trachomatis, N. gonorrhoeae, and T. vaginalis by RNA amplification; 41 6 .6% of the patients yielded a positive result for T. vaginalis, with a mean age 39.9 years (P < 0.0001 versus the mean ages for C. trachomatis and N. gonorrhoeae).
STI agent distribution by age decade ( 
Laboratory Diagnosis
Non-molecular modalities
The success of non-molecular means of T. vaginalis detection is largely depenent on the organism burden or disease prevalence. Wet-mount analysis involves collection of a vaginal swab, placement of the swab into physiologic saline (vaginal saline suspension), followed by microscopic observation of the suspension for motile flagellates using a high-power objective. This technique may have its best application in remote and underserved locales that may also experience financial constraints. In a study of Sudanese women attending a gynecologic clinic and experiencing a mean 14.4-day duration of symptoms, Saleh et al. 3 reported 99.2% wet-mount sensitivity compared to the performance of inhouse T. vaginalis PCR. In contrast, from a London STI clinic with 9.8% T. vaginalis prevalence via a composite reference standard, Nathan et al. [44] reported wet-mount sensitivity of 38%. In a U.S.
population with nearly 30% T. vaginalis prevalence, Nye et al. 45 45 noted a similar paradigm when assessing commercial TMA and an in-house PCR for T. vaginalis.
Using a molecularly resolved algorithm, the sensitivities of commercial T. vaginalis TMA on 296 firstvoid female urine, endocervical, and vaginal specimens were 87.5%, 89.8%, and 96.6%, respectively.
The analogous values derived from PCR were 76.1%, 80.9%, and 83.0%. From 298 first-void male urine and urethral swab specimens, the sensitivity of commercial TMA ranged from 73.8% (urine) to 95.2% 
trachomatis/M. genitalium/T. vaginalis-Multiprime-FRT
PCR kit (InterLabScience, Moscow, Russia) is a multiplex real-time PCR assay that requires an off-line DNA extraction step. Rumyantseva et al. 58 investigated its performance using first-void urine from 554 males, first-void urine from 498 females, and 209 vaginal swabs. T. vaginalis assessment was difficult on the basis of just one positive reference specimen in the evaluation. The assay was also limited in its capacity to detect Mycoplasma genitalium from both male and female specimens.
Additional modalities under development include a point-of-care cartridge (Atlas Genetics, Wiltshire, UK) that manages DNA extraction, amplification, and detection within 30 minutes using molded subcircuits. The final output is an electrochemical signal obtained using differential pulse voltammetry.
Pearce et al. 59 assessed a single-analyte T. vaginalis assay with 90 self-collected vaginal swabs previously tested by the Aptima Trichomonas vaginalis Assay. Sensitivity and specificity indices of 95.5% and 95.7%, respectively, were reported. The detection limit of the assay was five T. vaginalis organisms. As part of an investigational FilmArray nested-PCR panel for the identification of nine STI agents (BioFire Diagnostics, Salt Lake City, UT), Kriesel et al. 60 identified T. vaginalis DNA from 9 of 295 clinical specimens. However, not all the specimens were assessed with a predicate device.
Finally, recent proof-of-concept studies have discussed detection of T. vaginalis by loop-mediated isothermal amplification 61 and PCR-based microarray. 62 Value of T. vaginalis screening
The CDC recommendations for T. vaginalis diagnostic testing, using highly sensitive and specific modalities, apply to females seeking care for vaginal discharge. 11 The screening recommendations extend to persons receiving care in high-prevalence settings (correctional facilities and STI clinics) and to individuals with high-risk STI behavior (commercial sex workers, illicit drug use, and persons with multiple sexual partners or a history of STI). Moreover, local T. vaginalis epidemiology may influence screening decisions. 11 The scope of trichomoniasis may extend beyond these demographics, as Tomas et al. 63 vaginalis compared to an interval when only wet-mount testing was offered. In addition, significant reductions in both clinician requisition of wet-mount analysis and clinician performance of point-ofcare wet-mount microscopy was observed. Although NAAT yielded 38% more T. vaginalis detection than culture in one study, the prospect of universal screening may be somewhat tempered in lowerprevalence settings. 7 
Asymptomatic patients
One concern about T. vaginalis molecular screening is the unnecessary laboratory diagnosis of asymptomatic patients, 66 with a corollary being that less sensitive assays that detect higher organism Because nearly 50% of patients positive for T. vaginalis at baseline received therapy, the authors speculate that incident T. vaginalis was related to re-infection or treatment failure. Gaydos et al. 70 studied 304 female repeat participants in an internet STI screening program. Within this cohort, the T. vaginalis TMA detection rate was 7.9% during the first assessment, with 9.2% detection upon repeat testing (60% reporting symptoms). T. vaginalisdetection among repeat participants was also associated with previous detection of T. vaginalis (P < 0.05).
Final notes on specimen collection
Recent data from the CDC 71 support the collection of vaginal swabs for laboratory detection of C. trachomatis and N. gonorrhoeae. Such collections are preferred for assessment of T.
vaginalis infection; this preference is substantiated by data from Nye et al. 45 Other studies in the literature espouse first-void urine as a viable specimen option for detection of T. vaginalis in females.
Napierala et al. 24 reported a 12.6% T. vaginalisdetection rate from first-void urine in contrast to 8.9%
and 8.6% rates from endocervical and vaginal specimens, respectively. A follow-up assessment of 2,478
females from a large metropolitan cohort (including both high-and low-prevalence locales) 72 reported increased T. vaginalis detection from first-void urine (11.3%) compared to endocervical specimens (8.2%; P = 0.04) and a trend toward increased detection from first-void urine versus a combined endocervical/vaginal specimen data set (P = 0.06). The above-mentioned studies are limited because data analysis was based on the specimens collected by clinicians during routine medical practice; multiple specimens were not collected from the same patient. However, Andrea and Chapin 50 reported 11.5% and 3.2% T. vaginalis detection rates from female first-void urine and endocervical collection, respectively (P < 0.0002).
When C. trachomatis and T. vaginalis detection rates were compared in a demographic (under age 21) in which T. vaginalis is not typically considered within an STI differential diagnosis (Fig. 2) , the C. trachomatis detection rate among approximately 1,500 females was higher than that of T.
vaginalis (P = 0.001). However, when the detection rates were stratified by specimen source, 25 the T.
vaginalis detection rate (11.2%) among nearly 300 females who were screened with first-void urine rivaled the rate for C. trachomatis (10.9%; P = 0.92). First-void urine screening seemingly eliminated a disparity between African American and Caucasian female demographics with respect to T. vaginalis detection. Overall, TMA detection of the parasite in African American majority geographic locales across a large metropolitan area was 11.7% compared to 9.0% in predominantly Caucasian locales (P = 0.004). When stratified by first-void urine collection, T. vaginalis detection rates exhibited minimal difference (14.4% and 12.5% in African American and Caucasian majority locales, respectively; P = 0.54). 25 Gaydos et al. 73 described 3.7% detection of T. vaginalis RNA from 1,699 males using self-collected penile-meatal swabs in the context of an Internet screening program. Similar to previous studies of trichomoniasis epidemiology in males, the associated risk factors included age 30 to 39 years (odds ratio, 6.63) and age >40 years (odds ratio, 5.31). In a second cohort, Dize et al. 74 investigated concomitant submission of self-collected penile-meatal swabs and first-void urine from 634 males.
From 56 patients with detectable T. vaginalis infection via TMA, the swab sensitivity was 80.4% and the first-void urine sensitivity was 39.3%; similar disparities in sensitivity were observed for C. trachomatis and N. gonorrhoeae.
Conclusion
Evaluation of reports regarding past modalities for diagnosis of trichomoniasisis compromised by an evolving molecular reference standard. This is further confounded by analytical sensitivity differences between DNA and RNA amplification methods demonstrated both in vitro and in the clinical setting.
However, these recently commercialized, highly accurate diagnostic modalities, particularly those based on TMA, are facilitating "new" outlooks on the "old" epidemiology of trichomoniasis. This clinical entity is now widely distributed in a geographic setting, in both genders, and in wide range of age demographics. Evidence increasingly supports the value of T. vaginalismolecular diagnostics in the assessment of both symptomatic and asymptomatic populations. In conclusion, molecular assays for trichomoniasis, including those adapted to laboratory-modified testing formats, have the potential to impact public health and clinical practice.
